** Shares of gene-sequencing equipment maker Illumina ILMN.O fall 2.7% to $94.6
** Bernstein analysts say Roche's ROG.S new gene sequencing device designed to decode diseases such as cancer, immune disorders and neurodegenerative diseases outperforms ILMN's devices
** ROG unveiled the device on Thursday, featuring gene sequencing capabilities that provides detailed insights into genetics, genomics and cell biology
** ILMN shares had closed down 5.6% on Thursday, following the news
** Bernstein raises questions about the accuracy of the ROG device but said it could be a serious threat to ILMN in some applications
** ILMN has fallen 24.8% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。